case_images: PMC11026605_01
case_images: Diagnostic and treatment imaging. (A) Thoracic enhanced CT diagnosis. (B) Enhanced CT manifestation of hepatic cavernous hemangioma. (C) Skin reactions to RCCEP before and after apatinib treatment. (D) Pathological examination of hepatic cavernous hemangioma.
case_images: fimmu-15-1387465-g001.jpg
case_images: PMC11026605_04_fimmu-15-1387465-g001.jpg
case_images: f1
case_images: After 12 therapy cycles including camrelizumab, dynamic contrast-enhanced CT scans of the abdomen on January 24, 2022, and February 21, 2022, revealed an abnormal intensification in the liver's S7 segment from arterial to venous phase, suggestive of hepatic cavernous hemangioma (illustrated in the  Supplementary Figure 1 ).
case_images: Treatment timeline for Case 1. Illustrates the sequence and duration of treatments administered to the first case.
case_images: fimmu-15-1387465-g002.jpg
case_images: PMC11026605_05_fimmu-15-1387465-g002.jpg
case_images: f2
case_images: Figure 2 ). Further chemotherapy commenced on January 28, 2021.
case_images: PMC11026605_02
case_images: Case 2 hepatic cavernous hemangioma imaging. Enhanced CT visualization of hepatic cavernous hemangioma in the second case.
case_images: fimmu-15-1387465-g003.jpg
case_images: PMC11026605_06_fimmu-15-1387465-g003.jpg
case_images: f3
case_images: During the venous phase, patchy low-density shadows were observed in the superior segment of the right anterior lobe, with the density in the delayed phase being slightly higher than that of the adjacent liver tissue, suggestive of an atypical hemangioma (see the  Supplementary Figure 3 ).
case_images: PMC11026605_03
case_images: Case 3 hepatic cavernous hemangioma imaging. Combined enhanced CT and MRI manifestations of hepatic cavernous hemangioma in the third case.
case_images: fimmu-15-1387465-g004.jpg
case_images: PMC11026605_03_fimmu-15-1387465-g004.jpg
case_images: f4
case_images: Subsequent CT scans showed that the hepatic lesions had disappeared as of January 16, 2024 (see  Figure 4 ).
case_images: PMC11026605_04
case_images: Diagnostic and treatment imaging. (A) Thoracic enhanced CT diagnosis. (B) Enhanced CT manifestation of hepatic cavernous hemangioma. (C) Skin reactions to RCCEP before and after apatinib treatment. (D) Pathological examination of hepatic cavernous hemangioma.
case_images: fimmu-15-1387465-g001.jpg
case_images: PMC11026605_04_fimmu-15-1387465-g001.jpg
case_images: f1
case_images: After 12 therapy cycles including camrelizumab, dynamic contrast-enhanced CT scans of the abdomen on January 24, 2022, and February 21, 2022, revealed an abnormal intensification in the liver's S7 segment from arterial to venous phase, suggestive of hepatic cavernous hemangioma (illustrated in the  Supplementary Figure 1 ).
case_images: PMC11026605_05
case_images: Treatment timeline for Case 1. Illustrates the sequence and duration of treatments administered to the first case.
case_images: fimmu-15-1387465-g002.jpg
case_images: PMC11026605_05_fimmu-15-1387465-g002.jpg
case_images: f2
case_images: Figure 2 ). Further chemotherapy commenced on January 28, 2021.
case_images: PMC11026605_06
case_images: Case 2 hepatic cavernous hemangioma imaging. Enhanced CT visualization of hepatic cavernous hemangioma in the second case.
case_images: fimmu-15-1387465-g003.jpg
case_images: PMC11026605_06_fimmu-15-1387465-g003.jpg
case_images: f3
case_images: During the venous phase, patchy low-density shadows were observed in the superior segment of the right anterior lobe, with the density in the delayed phase being slightly higher than that of the adjacent liver tissue, suggestive of an atypical hemangioma (see the  Supplementary Figure 3 ).